coiaward2010

RCE-ESO-ESMO training course for rare cancer patient advocates: Travel grants available

article nov

Are you are Patient Advocate for Rare Cancers? If so, you need to know about the Training  Course from RCE-ESO-ESMO with travel grants available.

From 01-03 December 2018, the Rare Cancers Europe (RCE) initiative, in collaboration with the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO), is organising a specific training course for Rare Cancer Patient Advocates. 

The 2018 edition of the event will bring together patient advocates from across Europe, to exchange views and ideas with clinicians and researchers, who are attending the parallel ESO-ESMO-RCE Preceptorships and Clinical Update on Rare Adult Solid Cancers. 

Patient advocate travel grants available: Deadline 11th November

Rare Cancers Europe and ESMO are very pleased to offer a limited number of travel grants to enable European cancer patient advocates to attend this course. The deadline for sending applications is this weekend on 11 November 2018, so please act quickly.

Saturday 1st of December is specifically focused on the ESO-ESMO-RCE Clinical Update on Rare Cancers event. Rare cancers patient advocates are welcome to join sessions of their preferences and discuss ideas with oncologists and researchers.

Sunday and Monday offer Patient Advocates parallel sessions on challenges, understanding European initiatives, most importantly also a PA’s braining storming session and ending with Lobbying; Speaking up for Rare Cancers. You can see the draft agenda HERE

All the information available about the course and how to apply for a travel grant is HERE.

CML patient advocates applications

We encourage our European CML patient advocates to take advantage of this interesting training opportunity that enables you to Learn and Grow as Advocates in Rare Cancers and CML!

- Chronic Myeloid Leukemia is a rare disease and the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases. Its annual incidence has been estimated at between 1 and 1.5 cases per 100,000 and its prevalence at around 1 in 17,000. -

Please donate!

Please donate!

LogIn

EU e-Privacy Directive